# Glucagon

Canonical source: https://retacompare.com/encyclopedia/glucagon

Activates the glucagon receptor on hepatocytes, driving glycogenolysis and gluconeogenesis to raise blood glucose.

Reference facts

Also known asGlucaGen, Baqsimi, GvokeCategoryGLP-1 & MetabolicMechanism of actionActivates the glucagon receptor on hepatocytes, driving glycogenolysis and gluconeogenesis to raise blood glucose.TargetsGCGRIndications under research or approvedSevere Hypoglycemia, Diagnostic adjunct in radiologyRegulatory status (reference entry)FDA-approved (multiple formulations)Half-life~3–6 minutesSequenceHSQGTFTSDYSKYLDSRRAQDFVQWLMNTSequence notes29-residue counter-regulatory peptide hormone secreted by pancreatic alpha cells.Molecular weight (Da)3485PDB accession1GCNOriginator / sponsorEli Lilly, Novo Nordisk, XerisFirst reported1923
    Primary References

Baqsimi (nasal glucagon) FDA label


    Explore research articles about Glucagon


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Baqsimi (nasal glucagon) FDA label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210134s000lbl.pdf